Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
, 12 (9), 1329-35

Role of Cholecystokinin and Central Serotonergic Receptors in Functional Dyspepsia

Editorial

Role of Cholecystokinin and Central Serotonergic Receptors in Functional Dyspepsia

Andrew Seng Boon Chua et al. World J Gastroenterol.

Abstract

Symptoms of functional dyspepsia are characterized by upper abdominal discomfort or pain, early satiety, postprandial fullness,bloating, nausea and vomiting. It is a chronic disorder, with symptoms more than 3 mo per year,and no evidence of organic diseases. Dysfunctional motility, altered visceral sensation, and psychosocial factors have all been identified as major pathophysiological mechanisms. It is believed that these pathophysiological mechanisms interact to produce the observed symptoms. Dyspepsia has been categorized into three subgroups based on dominant symptoms. Dysmotility-like dyspepsia describes a subgroup of patients whose symptom complex is usually related to a gastric sensorimotor dysfunction. The brain-gut peptide cholecystokinin (CCK) and serotonin (5-HT) share certain physiological effects. Both have been shown to decrease gastric emptying and affect satiety. Furthermore the CCK induced anorexia depended on serotonergic functions probably acting via central pathways. We believe that abnormalities of central serotonergic receptors functioning together with a hyper responsiveness to CCK or their interactions may be responsible for the genesis of symptoms in functional dyspepsia (FD).

Figures

Figure 1
Figure 1
A :Prolactin response to buspirone challenge in healthy controls and patients with functional dyspepsia and peptic ulcer disease B :Prolactin response to buspirone 60 mg in male functional dyspeptics, peptic ulcer disease patients and healthy controls.
Figure 2
Figure 2
A: Response to CCK-8 challenge in healthy controls, patients with functional dyspcpsia and peptic ulcer disease; B: Effects of atropine on CCK-8 infusion in functional dyspeptic patients. C: Effects of loxiglumide 800mg on CCK-8 infusion in functional dyspeptic patients; D: Solid phase emptying rates in functional dyspeptic patients and healthy controls.

Similar articles

See all similar articles

Cited by 9 articles

See all "Cited by" articles

Publication types

Feedback